6
Clinical Trials associated with SR-1375A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SR1375 in Hospitalized Adult Patients With Community-acquired Pneumonia
This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of SR1375 in Hospitalized Patients With Pneumonia
Start Date19 Jan 2023 |
Sponsor / Collaborator- |
A Phase I Bridging Study to Evaluate the PK, PD, Safety and Tolerability of SR1375 in Healthy Subjects
This is a randomized, double-blind, placebo-controlled phase I bridging study to evaluate the PK, PD, safety and tolerability of SR1375 in healthy subjects.
100 Clinical Results associated with SR-1375
100 Translational Medicine associated with SR-1375
100 Patents (Medical) associated with SR-1375
100 Deals associated with SR-1375